European Global Exporters' Earnings Showcase Impact of a Weaker Euro

Global Head of Research

As HEDJ, the WisdomTree Europe Hedged Equity Fund recently crossed $15 billion in assets, we’ve been particularly interested to see how global exporters within Europe have been responding to a weaker euro.   Recap of Where the Euro Moved in 2014 and Where It Has Been Heading in 20151 • The euro ended 2013 at $1.37 and didn’t move much in the first half of the year, ending the first quarter at $1.38 and the second quarter at $1.37.   • The second half of the year was a different story, with the euro ending the third quarter at $1.26 and then finishing 2014 at $1.21.   • As of March 13, 2015, the euro was below $1.05.   Matching Our Intuition to Real-World Results One large holding in the WisdomTree Europe Hedged Equity Index (the Index HEDJ is designed to track) is Sanofi. As of December 31, 2014, it represented a 4.40% weight in the Index, making it the fifth largest holding overall.2 Sanofi’s February 5, 2015, earnings report provides the perfect example of how European exporters have been responding to a weaker euro. Intuitively, we’d expect that Sanofi’s results would show the stronger euro as a headwind, having appreciated in a fairly steady trend since the summer of 2012 when it hit a low of $1.213. The critical question—did the fourth quarter of 2014, when the euro was substantially weakened, look any different from the first three quarters of 2014?   Sanofi’s Fourth-Quarter Results Indicate Emergence of a Euro Tailwind Quantifying the Euro Tailwind: While the overall impact of the euro on Sanofi’s net sales was negative when taking the full year into account, we call attention to the fact that the fourth quarter saw a positive currency impact of nearly a quarter of a billion euros. Similarly, the impact on business earnings per share was about 0.02 euros 4.   • Sanofi’s Thoughts on 2015: Within its company presentation, Sanofi said that if December 31, 2014, exchange rates were applied to its 2015 forecasts, business earnings per share could potentially increase 4% to 5%. Of course, this is an estimate and by no means certain, but it’s worth noting that the December 31, 2014, euro exchange rate was $1.21, whereas the exchange rate on February 5, 2015—the day these results were released—was $1.15.5 With Mario Draghi’s January 22, 2015, announcement that the European Central Bank would embark on quantitative easing, the case for a strengthening euro has become more difficult to make, so it’s possible that Sanofi’s first-quarter 2015 results could reflect an even lower euro exchange rate.   Sanofi Returns More Cash to Shareholders Sanofi certainly covered more than just the impact of the euro currency in the announcement of its results, and we found two additional points of central interest.6 1. 21st Consecutive Annual Dividend Increase: The company proposed a dividend for the 2014 year of 2.85 euros per share, which would represent its 21st consecutive year of a dividend increase, as well as a payout ratio of nearly 55%. 2. Increase in Net Share Buybacks of Nearly 500 Million Euros: In 2014, Sanofi’s increase in net buyback activity was 484 million euros, to a total of 1.1 billion euros. It’s worth noting that the firm’s net buybacks as recently as 2012 were less than 200 million euros, so this represents significant growth.   Economic Growth and Profit Growth Can Be Quite Different Europe’s lackluster economic growth and potential for disinflation to become deflation have been widely publicized, and they are major contributing factors to Draghi’s January 22, 2015, blockbuster quantitative easing announcement. However, Sanofi’s results show us that profit growth and positive results at the company level are not necessarily connected directly to economic growth—especially for significant exporters. Sanofi is a great example of a truly global company that just happens to be incorporated within Europe, and it is a good example of the type of firm that the WisdomTree Europe Hedged Equity Index generates exposure to.         1Source for three bullets: Bloomberg, with data as of specified periods. 2Sanofi had a 4.32% weight in HEDJ as of 12/31/14. 3Source: Bloomberg, as of 7/24/12 when the euro hit $1.2061. 4Source: Annual Results 2014, Sanofi presentation, 2/5/15. 5Source: Bloomberg, with levels of euro measured as of 12/31/14 and 2/5/15. 6Source for both bullets: Annual Results 2014, Sanofi presentation, 2/5/15.

Important Risks Related to this Article

There are risks associated with investing, including possible loss of principal. Foreign investing involves special risks, such as risk of loss from currency fluctuation or political or economic uncertainty. Investments in currency involve additional special risks, such as credit risk and interest rate fluctuations. Derivative investments can be volatile, and these investments may be less liquid than other securities, and more sensitive to the effects of varied economic conditions. As this Fund can have a high concentration in some issuers, the Fund can be adversely impacted by changes affecting those issuers. Due to the investment strategy of this Fund, it may make higher capital gain distributions than other ETFs. Please read the Fund’s prospectus for specific details regarding the Fund’s risk profile. Dividends are not guaranteed, and a company’s future ability to pay dividends may be limited. A company currently paying dividends may cease paying dividends at any time.

For more investing insights, check out our Economic & Market Outlook


About the Contributor
Global Head of Research

Christopher Gannatti began at WisdomTree as a Research Analyst in December 2010, working directly with Jeremy Schwartz, CFA®, Director of Research. In January of 2014, he was promoted to Associate Director of Research where he was responsible to lead different groups of analysts and strategists within the broader Research team at WisdomTree. In February of 2018, Christopher was promoted to Head of Research, Europe, where he was based out of WisdomTree’s London office and was responsible for the full WisdomTree research effort within the European market, as well as supporting the UCITs platform globally. In November 2021, Christopher was promoted to Global Head of Research, now responsible for numerous communications on investment strategy globally, particularly in the thematic equity space. Christopher came to WisdomTree from Lord Abbett, where he worked for four and a half years as a Regional Consultant. He received his MBA in Quantitative Finance, Accounting, and Economics from NYU’s Stern School of Business in 2010, and he received his bachelor’s degree from Colgate University in Economics in 2006. Christopher is a holder of the Chartered Financial Analyst Designation.